| HOME >> BIOLOGY >> TECHNOLOGY |
Mesothelioma develops in the chest outside the lungs, usually growing asymptomatically before it is discovered. It is especially common in people who have been exposed to asbestos, such as ship yard workers and pipefitters. Each year, an estimated 2,500 to 3,000 people are diagnosed with mesothelioma in the United States and it accounts for more than 2,500 deaths in the United States. It accounts for approximately 43,000 deaths worldwide each year.
For more information about the trial, call 1-888-422-4743.
About Morphotek
Morphotek, Inc., a subsidiary of Eisai Corporation of North America, is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology. The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit http://www.morphotek.com.
About Eisai Corporation of North America
Eisai Corporation of North America is a wholly-owned
'/>"/>
| SOURCE Morphotek, Inc. Copyright©2009 PR Newswire. All rights reserved |